BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

  September 16, 2024

   · 

  19 min read
• Press Releases

  Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

  September 16, 2024

   · 

  6 min read
• Press Releases

  Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

  September 16, 2024

   · 

  3 min read
• Press Releases

  Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

  September 16, 2024

   · 

  9 min read
• Press Releases

  Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

  September 16, 2024

   · 

  8 min read
• Press Releases

  Adela Announces Clinical Validation Results for Head & Neck Cancer MRD Test Simultaneously Published in Annals of Oncology and Presented at ESMO 2024

  September 16, 2024

   · 

  6 min read
• Press Releases

  RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer

  September 16, 2024

   · 

  29 min read
• Press Releases

  Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

  September 16, 2024

   · 

  8 min read
• Press Releases

  KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma

  September 16, 2024

   · 

  19 min read
• Press Releases

  New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

  September 16, 2024

   · 

  11 min read